What is the recommended management of allergic rhinitis in children?

Management of Allergic Rhinitis in Children

Intranasal corticosteroids should be the first-line treatment for moderate-to-severe allergic rhinitis in children, as they are superior to all other monotherapies and have an excellent safety profile even with long-term use. 1

Initial Treatment Approach

First-Line Therapy: Intranasal Corticosteroids

• Start with intranasal corticosteroid monotherapy (fluticasone propionate, fluticasone furoate, or mometasone) for all children with moderate-to-severe allergic rhinitis. 1
• Intranasal corticosteroids are more effective than oral montelukast, producing greater reductions in total nasal symptom scores and meeting minimal clinically important differences. 1
• These agents have minimal systemic absorption and a safety profile comparable to placebo in high-quality trials. 1
• Once-daily dosing improves adherence and potentially decreases systemic side effects. 2
• Generic formulations are now widely available and cost-effective. 1

Why Intranasal Corticosteroids Are Superior

• They effectively target type 2 inflammation that drives allergic rhinitis, particularly addressing nasal congestion which depends on vasodilation and increased mucus production. 3
• They reduce eosinophilic infiltrate of the nasal mucosa and effectively control post-nasal drip by decreasing mucus production. 1, 3
• Newer agents (mometasone furoate, fluticasone furoate) have improved risk-benefit ratios with low systemic bioavailability, making long-term treatment safer in children. 4, 2

Step-Up Therapy for Inadequate Response

When Intranasal Corticosteroid Alone Fails

• Add intranasal antihistamine (azelastine) to the intranasal corticosteroid if symptoms persist. 1
• This combination yields superior efficacy with symptom score reductions of -5.3 to -5.7 on a 24-point scale versus -3.8 to -5.1 for corticosteroid alone. 1
• Fixed-combination intranasal antihistamine plus corticosteroid sprays are very effective but indicated for adolescents only (not younger children). 3, 5

Do NOT Add Oral Antihistamines to Intranasal Corticosteroids

• Adding oral antihistamines (e.g., fexofenadine) to intranasal corticosteroids provides no additional clinical benefit and is not recommended. 1
• Moderate-quality evidence supports a strong recommendation against routine combination therapy with oral antihistamines. 1

Alternative Oral Therapy (Second-Line)

When to Consider Oral Medications

Use montelukast plus oral antihistamine only in these specific situations: 1

• The child cannot tolerate intranasal sprays due to epistaxis, irritation, or aversion
• The child has concurrent mild persistent asthma where montelukast offers dual benefit
• Strong patient/family preference for oral medication despite lower efficacy

Important caveat: This oral regimen is less effective than intranasal corticosteroids but acceptable as a secondary option. 1 Montelukast carries FDA warnings for possible neuropsychiatric events that must be discussed with families.

Symptom-Specific Considerations

For Histamine-Mediated Symptoms

• Oral or intranasal antihistamines are particularly indicated for itching, sneezing, and watery rhinorrhea (histamine-dependent symptoms). 3
• Newer-generation oral H1-antihistamines (e.g., bilastine 10 mg/day for children 2-12 years) are nonsedating and effective for allergic rhinoconjunctivitis. 6

For Nasal Congestion

• Nasal congestion requires corticosteroids as it is closely associated with type 2 inflammation rather than histamine release. 3
• Intranasal corticosteroids are the most effective pharmacologic treatment for this symptom. 2

Adjunctive Measures

Nasal Lavage

• Nasal lavage is safe, cheap, and adequate for all children with allergic rhinitis. 3
• It removes secretions, allergens, and mediators from the nasal mucosa. 3
• Hypertonic solutions exert additional decongestant activity. 3

Allergen Avoidance

• Removing or avoiding triggering allergens should always be advised alongside pharmacotherapy. 7, 2

Severe or Refractory Cases

Allergen-Specific Immunotherapy

• Immunotherapy is the only causal treatment and should be considered for severe cases poorly controlled with pharmacotherapy. 3, 8
• It must be tailored to the specific causing allergen identified through skin prick testing or in vitro allergen-specific IgE tests. 4, 8
• This approach has disease-modifying effects and potential long-term benefits. 7

Classification and Monitoring

Disease Classification

• Classify as intermittent versus persistent (not just seasonal versus perennial), as introduced by ARIA in 2001. 9
• Assess severity as mild versus moderate-to-severe based on impact on quality of life, school performance, and sleep. 9

Key Outcomes to Monitor

• Combined nasal symptoms, ocular symptoms, quality of life, and school performance are critical outcomes. 9
• Visual analogue scales and mobile applications facilitate monitoring and optimize patient self-management. 8

Important Caveats

Extrapolation from Adult Data

• Almost all studies supporting ARIA guidelines included exclusively adult patients, requiring careful extrapolation to children. 9
• Relative treatment effects are likely similar, but adverse effects may differ in frequency and perception (e.g., bitter taste). 9
• Values and preferences for specific outcomes vary between adults and children. 9

Systemic Decongestants

• Avoid systemic decongestants in children as they are associated with irritability and insomnia. 2

First-Generation Antihistamines

• Avoid first-generation antihistamines due to dry mouth and sedation, which impair school performance. 2

Comorbid Conditions

• Allergic rhinitis usually occurs with other allergic conditions, particularly allergic conjunctivitis and asthma. 3, 4
• Treatment must address the full spectrum of allergic disease for optimal outcomes. 4